DALLAS, July 30, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Generex Biotechnology Corp. (Nasdaq:GNBT). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/GNBT
The MACD for GNBT currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above zero, which implies that the underlying moving averages are trending higher.
Generex Biotechnology Corp. (GNBT) is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its wholly owned subsidiaries include Generex Pharmaceuticals Inc., Antigen Express Inc., Generex (Bermuda) Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc. The Company is in development stage. In September 2009, the Company announced the incorporation of SIA Generex Biotechnology BALTIC as a wholly owned subsidiary.
Message Board Search for GNBT: http://www.boardcentral.com/boards/GNBT
In the report, the analyst notes:
"GNBT's net loss for the quarter ended April 30, 2010, was $4,567,550 versus $11,349,015 in the corresponding quarter of the prior fiscal year. The decrease in net loss in this fiscal quarter versus the corresponding quarter of the prior fiscal year is primarily due to the prior year's quarter interest expense of $5,344,911, which consisted mainly of non-cash interest charges recorded in connection with the Company's secured convertible debentures and the $2,776,278 gain on revaluation of the derivative in the current year's quarter. Interest expense for the current year quarter was $53,326.
"GNBT, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, recently announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six-month pivotal global phase 3 study of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product."
To read the entire report visit: http://www.microstockprofit.com/lp/GNBT
See what investors are saying about GNBT at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.